Physician profile
Carol Abalihi
NPI 1326136243
$4,226.50
in general payments reported to CMS, 2019-2025
29 companies · $2,459 in 2025
The $2,459 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $283 · 2021: $392 · 2022: $329 · 2023: $39.92 · 2024: $299 · 2025: $2,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471 · Travel and Lodging: $1,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.65 |
| Travel and Lodging | $1,326.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $2,047.01 | 2019-2025 | Pico, Collagenase Santyl, Versajet |
| Biofire Diagnostics, LLC | $382.00 | 2019-2021 | |
| Medtronic, INC. | $249.15 | 2022 | |
| Lilly USA, LLC | $215.79 | 2020-2024 | Mounjaro |
| Novo Nordisk INC | $192.16 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $169.10 | 2019-2022 | |
| Biowound Solutions, INC. | $155.26 | 2025 | Bio-Connekt |
| Globus Medical, INC. | $102.82 | 2025 | Senza |
| Inari Medical, INC. | $83.52 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Pfizer INC. | $74.55 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $64.30 | 2024-2025 | Airsupra |
| Depuy Synthes Sales INC. | $60.20 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $50.02 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.75 | 2023-2024 | |
| Abbott Laboratories | $45.15 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $43.93 | 2021 | |
| Phathom Pharmaceuticals, INC. | $33.39 | 2025 | Voquezna |
| Boston Scientific Corporation | $24.18 | 2025 | General - Erectile Dysfunction |
| Ucb, INC. | $23.10 | 2021 | |
| Kerecis Limited | $20.55 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Sanofi-Aventis U.S. LLC | $20.48 | 2021 | |
| Convatec INC. | $18.92 | 2025 | |
| Roche Diagnostics Corporation | $17.88 | 2020 | |
| Amarin Pharma, INC. | $17.11 | 2020 | |
| Sunovion Pharmaceuticals INC. | $16.85 | 2019 | |
| Genentech USA, INC. | $16.22 | 2019 | |
| Hartmann USA, INC. | $16.10 | 2025 | Colactive Plus 2x2 |
| Abbvie INC. | $11.24 | 2021 | |
| Reprise Biomedical, INC. | $8.77 | 2025 | Mirotract |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Abalihi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.